LYPD6B

Across TCGA pan-cancer cohorts, LYPD6B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LYPD6B data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LYPD6B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYPD6B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, LGG, and UCEC are the cancer types where LYPD6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.057	0.680	<.001	12	view →
LGG	DFS	Median	All	0.142	0.738	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.634	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LYPD6B–LUAD (OS)

Open the LUAD breakdown →